News
DTIL
13.56
+4.47%
0.58
Buy Rating Affirmed for Precision BioSciences on Promising Gene Editing Prospects and Strong Financials
TipRanks · 18h ago
Precision Biosciences Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 18h ago
HC Wainwright & Co. Maintains Buy on Precision BioSciences, Adjusts Price Target To $60
Benzinga · 18h ago
Precision Biosciences Battles Delisting Risk: Reverse Split to Rescue Stock Price
TipRanks · 1d ago
Buy Rating Affirmed for Precision BioSciences as Milestones in Gene Editing Technology Loom
TipRanks · 1d ago
DTIL Stock Earnings: Precision BioSciences Misses EPS, Misses Revenue for Q4 2023
Precision BioSciences reported earnings per share of -$3.35. The company reported revenue of $7.04 million. This was 43.61% worse than the analyst estimate for revenue of $12.48 million. The company's revenue was also below analyst estimates.
Investorplace · 1d ago
Precision BioSciences Inc reports results for the quarter ended in December - Earnings Summary
Precision BioSciences Inc reports results for the quarter ended in December. Revenue fell 33.6% to $7.04 million from a year ago. The company reported a quarterly adjusted loss of $4.06 per share. The mean expectation of four analysts was for a loss of $2.05.
Reuters · 1d ago
Precision BioSciences (DTIL) Reports Q4 Loss, Lags Revenue Estimates
NASDAQ · 1d ago
Precision BioSciences Inc Q4 Loss decreases, but misses estimates
NASDAQ · 1d ago
Precision BioSciences GAAP EPS of -$4.06 misses by $2.03, revenue of $7.04M misses by $7.42M
Precision BioSciences, Inc. Reports Q4 GAAP EPS of -$4.06 misses by $2.03. Q4 revenue of $7.04M misses by 33.5% Y/Y. The decrease in revenue was primarily due to a decrease in collaborations.
Seeking Alpha · 1d ago
Precision BioSciences Q4 GAAP EPS $(4.06) May Not Be Comparable To $(2.05) Estimate, Sales $7.04M Miss $12.48M Estimate
Precision BioSciences reported quarterly losses of $4.06 per share. The company reported quarterly sales of $7.04 million which missed the analyst consensus estimate of $12.48 million by 43.61%. The company also missed quarterly losses by 98.05 percent.
Benzinga · 1d ago
*Precision Biosciences 4Q Rev $7.04M >DTIL
Dow Jones · 1d ago
*Precision Biosciences 4Q Loss/Shr $4.06 >DTIL
Dow Jones · 1d ago
Earnings Scheduled For March 27, 2024
Local Bounti is projected to report quarterly loss at $2.41 per share on revenue of $8.70 million. Companies Reporting Before The Bell include REE Automotive and Lands' End. The companies are expected to report earnings for their fourth quarter before the bell.
Benzinga · 2d ago
Precision BioSciences: Q4 Earnings Snapshot
Precision BioSciences Inc. Reported a loss of $16.3 million in its fourth quarter. The genome editing company posted revenue of $7 million in the period. For the year, the company reported a Loss of $61.4 million. The company is based in Durham, North Carolina.
Barchart · 2d ago
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
Precision BioSciences, Inc. Announced financial results for the fourth quarter and fiscal year ended December 31, 2023. The company is developing in-vivo gene editing therapies using its novel ARCUS platform. The company's wholly owned programs include hepatitis B and mitochondrial DNA editing programs.
Barchart · 2d ago
Earnings Preview: Precision BioSciences
Precision BioSciences is set to give its latest quarterly earnings report on Wednesday, 2024-03-27. Analysts estimate the company will report an earnings per share of $-2.05. Last quarter the company beat EPS by $3.00 and shares were trading at $11.8.
Benzinga · 2d ago
Precision BioSciences Q4 Earnings Preview
Precision BioSciences, Inc. Is scheduled to announce Q4 earnings results on Wednesday, March 27th. The consensus EPS Estimate is -$2.03 and the consensus revenue estimate is $14.46 million. DTIL has beaten earnings estimates 50% of the time.
Seeking Alpha · 2d ago
Notable earnings before Wednesday's open
Seeking Alpha · 2d ago
Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Lags Revenue Estimates
NASDAQ · 3d ago
More
Webull provides a variety of real-time DTIL stock news. You can receive the latest news about Precision Biosciences through multiple platforms. This information may help you make smarter investment decisions.
About DTIL
Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company’s pipeline comprises in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. ARCUS is a natural homing endonuclease which allows precise gene editing, such as gene insertions, gene excision, and gene elimination. ARCUS is also relatively small size which potentially allows delivery to a range of cells and tissues using viral and non-viral gene delivery methods. ARCUS uses sequence-specific deoxyribonucleic acid (DNA)-cutting enzymes, or nucleases to insert (knock in), remove (knock out), or repair DNA of living cells and tissues. The Company’s in vivo gene editing programs include PBGENE-HBV, PBGENE-HbE, PBGENE-DMD, PBGENE-LLY2, PBGENE-LLY3, iECURE-OTC, and PBGENE-PMM. PBGENE-HBV is designed for the treatment of chronic hepatitis B virus (HBV).